Compound 5104434, a selective enzymatic reactivator of HDAC1 previously reported to exert beneficial effects in Alzheimer’s disease and experimental stroke models [7,10,14], was evaluated for its therapeutic efficacy in post-ischemic recovery. The gene discussed is HDAC1; the disease is early-onset autosomal dominant Alzheimer disease.